Novo Nordisk

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments.

CEO

Lars Fruergaard Jørgensen

CEOLars Fruergaard Jørgensen

Employees

76,302

Employees76,302

Headquarters

Bagsværd, Capital Region

HeadquartersBagsværd, Capital Region

Founded

1931

Founded1931

Employees

76,302

Employees76,302

NVO Key Statistics

Market cap

406.63B

Market cap406.63B

Price-Earnings ratio

27.66

Price-Earnings ratio27.66

Dividend yield

1.13%

Dividend yield1.13%

Average volume

9.12M

Average volume9.12M

High today

$91.61

High today$91.61

Low today

$89.28

Low today$89.28

Open price

$91.11

Open price$91.11

Volume

7.39M

Volume7.39M

52 Week high

$148.15

52 Week high$148.15

52 Week low

$77.82

52 Week low$77.82

NVO News

Sherwood News 1d

Here’s how Hims & Hers will pivot now that it can’t mass produce copies of Wegovy and Ozempic

The new focus for Hims & Hers on the weight-loss front will be... selling even older Novo Nordisk GLP-1 drugs. Hims & Hers has skidded 40% since the Food and D...

Seeking Alpha 2d

Drug compounders sue FDA over semaglutide status: report

Makers of copycat versions of Novo Nordisk's (NVO) popular weight-loss drug semaglutide, also known as Ozempic and Wegovy, are suing the FDA for removing the GL...

Seeking Alpha 4d

Lilly, Novo dominance to continue as TD Cowen lifts 2030 GLP-1 sales forecast by 38%

TD Cowen projects that with Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) continuing their dominance, global sales of the GLP-1 class of weight loss/obesity drugs...

Analyst ratings

69%

of 35 ratings

Buy

68.6%

Hold

28.6%

Sell

2.9%

More NVO News

TipRanks 5d

Shortage of Novo Nordisk’s Weight Loss Drugs Is Resolved, Says FDA

The shortage of Novo Nordisk’s (NVO) blockbuster weight loss drugs has been resolved, according to the U.S. Food and Drug Administration (FDA). Discover the Be...

Sherwood News 6d

Hims & Hers falls, Novo Nordisk rises after FDA says Ozempic shortage is over

Hims & Hers falls, Novo Nordisk rises after FDA says Ozempic shortage is over The popular weight-loss drugs Ozempic and Wegovy are no longer in a shortage, the...